Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2025-01-03T14:36:59.442Z Has data issue: false hasContentIssue false
  • English
  • Français

Response to “Germ Line Therapy to Cure Mitochondrial Disease: Protocol and Ethics of In Vitro Ovum Nuclear Transplantation” by Donald S. Rubenstein, David C. Thomasma, Eric A. Schon, and Michael J. Zinaman (CQ Vol 4, No 3)

Altering the Mitochondrial Genome: Is it Just a Technical Issue?

Published online by Cambridge University Press:  01 July 1999

Imre Szebik
Imre Szebik
Affiliation:
Clinical Trials Research Group, Biomedical Ethics Unit, at McGill University in Montreal, Quebec
Get access Rights & Permissions [Opens in a new window]

Abstract

Technical, ethical, and social questions of germ-line gene interventions have been widely discussed in the literature. The majority of these discussions focus on planned interventions executed on the nuclear DNA (nDNA). However, human cells also contain another set of genes that is the mitochondrial DNA (mtDNA). As the characteristics of the mtDNA grossly differ from those of nDNA, so do the social, ethical, psychological, and safety considerations of possible interventions on this part of the genetic substance.

Type
RESPONSES AND DIALOGUE
Information
Cambridge Quarterly of Healthcare Ethics , Volume 8 , Issue 3 , July 1999 , pp. 369 - 374
Copyright
© 1999 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)